Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. The company also engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal… Read more
Faes Farma SA (FAE) - Net Assets
Latest net assets as of December 2025: €747.70 Million EUR
Based on the latest financial reports, Faes Farma SA (FAE) has net assets worth €747.70 Million EUR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.34 Billion) and total liabilities (€594.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €747.70 Million |
| % of Total Assets | 55.72% |
| Annual Growth Rate | -11.81% |
| 5-Year Change | 38.96% |
| 10-Year Change | 162.46% |
| Growth Volatility | 23.06 |
Faes Farma SA - Net Assets Trend (2000–2025)
This chart illustrates how Faes Farma SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Faes Farma SA (2000–2025)
The table below shows the annual net assets of Faes Farma SA from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €747.70 Million | +2.90% |
| 2024-12-31 | €726.62 Million | +9.54% |
| 2023-12-31 | €663.35 Million | +10.14% |
| 2022-12-31 | €602.28 Million | +11.93% |
| 2021-12-31 | €538.07 Million | +13.79% |
| 2020-12-31 | €472.88 Million | +14.32% |
| 2019-12-31 | €413.65 Million | +14.85% |
| 2018-12-31 | €360.15 Million | +12.28% |
| 2017-12-31 | €320.77 Million | +12.60% |
| 2016-12-31 | €284.89 Million | +12.01% |
| 2015-12-31 | €254.34 Million | +11.25% |
| 2014-12-31 | €228.63 Million | +15.58% |
| 2013-12-31 | €197.81 Million | +7.03% |
| 2012-12-31 | €184.82 Million | +10.26% |
| 2011-12-31 | €167.61 Million | +1.27% |
| 2010-12-31 | €165.51 Million | +34.64% |
| 2009-12-31 | €122.93 Million | -21.56% |
| 2008-12-31 | €156.71 Million | +3.74% |
| 2007-12-31 | €151.06 Million | +8.01% |
| 2006-12-31 | €139.85 Million | +6.25% |
| 2005-12-31 | €131.62 Million | +0.94% |
| 2004-12-31 | €130.40 Million | +10.64% |
| 2003-12-31 | €117.86 Million | +8.72% |
| 2002-12-31 | €108.41 Million | -99.37% |
| 2001-12-31 | €17.10 Billion | -1.11% |
| 2000-12-31 | €17.29 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Faes Farma SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 94.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €181.83 Million | 24.41% |
| Common Stock | €31.62 Million | 4.25% |
| Other Comprehensive Income | €540.82 Million | 72.61% |
| Total Equity | €744.80 Million | 100.00% |
Faes Farma SA Competitors by Market Cap
The table below lists competitors of Faes Farma SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bittium Oyj
HE:BITTI
|
$1.05 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
$1.05 Billion |
|
Top Glove Corporation Bhd
PINK:TPGVF
|
$1.05 Billion |
|
Trinity Capital Inc
NASDAQ:TRIN
|
$1.06 Billion |
|
PDF Solutions Inc
NASDAQ:PDFS
|
$1.05 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
$1.05 Billion |
|
QUIDELORTHO DL-001
F:QL1A
|
$1.05 Billion |
|
L&T Technology Services Limited
NSE:LTTS
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Faes Farma SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 725,870,000 to 744,803,000, a change of 18,933,000 (2.6%).
- Net income of 79,630,000 contributed positively to equity growth.
- Dividend payments of 55,715,000 reduced retained earnings.
- Other comprehensive income increased equity by 33,349,000.
- Other factors decreased equity by 38,331,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €79.63 Million | +10.69% |
| Dividends Paid | €55.72 Million | -7.48% |
| Other Comprehensive Income | €33.35 Million | +4.48% |
| Other Changes | €-38.33 Million | -5.15% |
| Total Change | €- | 2.61% |
Book Value vs Market Value Analysis
This analysis compares Faes Farma SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.69x to 1.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | €0.46 | €4.49 | x |
| 2004-12-31 | €0.51 | €4.49 | x |
| 2005-12-31 | €0.52 | €4.49 | x |
| 2006-12-31 | €0.91 | €4.49 | x |
| 2007-12-31 | €0.87 | €4.49 | x |
| 2008-12-31 | €0.91 | €4.49 | x |
| 2009-12-31 | €0.58 | €4.49 | x |
| 2010-12-31 | €0.76 | €4.49 | x |
| 2011-12-31 | €0.77 | €4.49 | x |
| 2012-12-31 | €0.82 | €4.49 | x |
| 2013-12-31 | €0.82 | €4.49 | x |
| 2014-12-31 | €0.90 | €4.49 | x |
| 2015-12-31 | €0.97 | €4.49 | x |
| 2016-12-31 | €1.09 | €4.49 | x |
| 2017-12-31 | €1.19 | €4.49 | x |
| 2018-12-31 | €1.30 | €4.49 | x |
| 2019-12-31 | €1.51 | €4.49 | x |
| 2020-12-31 | €1.61 | €4.49 | x |
| 2021-12-31 | €1.76 | €4.49 | x |
| 2022-12-31 | €1.96 | €4.49 | x |
| 2023-12-31 | €2.13 | €4.49 | x |
| 2024-12-31 | €2.35 | €4.49 | x |
| 2025-12-31 | €2.38 | €4.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Faes Farma SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.69%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.04%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.80x
- Recent ROE (10.69%) is below the historical average (13.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 16.58% | 11.27% | 0.88x | 1.68x | €7.76 Million |
| 2004 | 18.26% | 14.60% | 0.82x | 1.53x | €10.76 Million |
| 2005 | 17.68% | 13.98% | 0.77x | 1.64x | €10.11 Million |
| 2006 | 16.29% | 12.30% | 0.80x | 1.66x | €8.79 Million |
| 2007 | 14.66% | 11.91% | 0.68x | 1.80x | €7.05 Million |
| 2008 | 12.52% | 10.10% | 0.71x | 1.76x | €3.95 Million |
| 2009 | 14.77% | 13.82% | 0.56x | 1.92x | €5.87 Million |
| 2010 | 12.09% | 9.88% | 0.68x | 1.80x | €3.45 Million |
| 2011 | 8.46% | 7.45% | 0.65x | 1.74x | €-2.58 Million |
| 2012 | 10.56% | 11.08% | 0.61x | 1.55x | €1.04 Million |
| 2013 | 11.43% | 12.53% | 0.63x | 1.44x | €2.83 Million |
| 2014 | 11.08% | 13.21% | 0.72x | 1.17x | €2.47 Million |
| 2015 | 11.94% | 14.83% | 0.70x | 1.14x | €4.93 Million |
| 2016 | 12.84% | 16.00% | 0.69x | 1.16x | €8.10 Million |
| 2017 | 13.18% | 15.38% | 0.64x | 1.34x | €10.20 Million |
| 2018 | 14.34% | 15.91% | 0.67x | 1.34x | €15.60 Million |
| 2019 | 15.49% | 17.90% | 0.72x | 1.20x | €22.67 Million |
| 2020 | 15.39% | 19.08% | 0.67x | 1.20x | €25.41 Million |
| 2021 | 15.36% | 20.67% | 0.62x | 1.20x | €28.74 Million |
| 2022 | 14.89% | 20.40% | 0.60x | 1.21x | €29.39 Million |
| 2023 | 13.88% | 20.37% | 0.58x | 1.17x | €25.67 Million |
| 2024 | 15.34% | 22.56% | 0.58x | 1.18x | €38.77 Million |
| 2025 | 10.69% | 13.04% | 0.45x | 1.80x | €5.15 Million |
Industry Comparison
This section compares Faes Farma SA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $213,950,000
- Average return on equity (ROE) among peers: 4.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Faes Farma SA (FAE) | €747.70 Million | 16.58% | 0.79x | $1.05 Billion |
| Laboratorio Reig Jofre S.A (RJF) | $213.95 Million | 4.85% | 0.61x | $54.17 Million |